Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review.

Autor:	Salter BS; Department of Anesthesiology, Mount Sinai Medical Center, New York, New York. Electronic address: benjamin.salter@mountsinai.org., Weiner MM; Department of Anesthesiology, Mount Sinai Medical Center, New York, New York., Trinh MA; Department of Anesthesiology, Mount Sinai Medical Center, New York, New York., Heller J; Department of Anesthesiology, Mount Sinai Medical Center, New York, New York., Evans AS; Department of Anesthesiology, Mount Sinai Medical Center, New York, New York., Adams DH; Department of Cardiac Surgery, Mount Sinai Medical Center, New York, New York., Fischer GW; Department of Anesthesiology, Mount Sinai Medical Center, New York, New York.
Jazyk:	angličtina
Zdroj:	Journal of the American College of Cardiology [J Am Coll Cardiol] 2016 May 31; Vol. 67 (21), pp. 2519-32.
DOI:	10.1016/j.jacc.2016.02.073
Abstrakt:	Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin or, less commonly, to low-molecular weight heparin. In this comprehensive review, the authors highlight heparin-induced thrombocytopenia's risk factors, clinical presentation, pathophysiology, diagnostic principles, and treatment. The authors place special emphasis on the management of patients requiring procedures using cardiopulmonary bypass or interventions in the catheterization laboratory. Clinical vigilance of this disease process is important to ensure its recognition, diagnosis, and treatment. Misdiagnosis of the syndrome, as well as misunderstanding of the disease process, continues to contribute to its morbidity and mortality. (Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu